Toxicology effects of *Berberis vulgaris* (barberry) and its active constituent, berberine: a review

Seyede Zohre Kamrani Rad 1, Maryam Rameshrad 1, 2, Hossein Hosseinzadeh 1, 2*

1Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
2Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

**Abstract**

*Berberis vulgaris* and berberine, its main component, traditionally have been used for treatment of various disorders. The pharmacological properties of them have been investigated using different *in vivo* and *in vitro* models. In spite of beneficial effects of *B. vulgaris* on different cell lines, there are documents have revealed negative impacts of it on animal and human. In this regards, the determination of its toxicity in a scientific view is necessary. In current report, we provide classified information about the toxicity of *B. vulgaris* and berberine in different conditions consist of acute, subacute, sub-chronic and chronic state. Besides, it discusses the cytotoxicity, genotoxicity, mutagenicity, and carcinogenicity of *B. vulgaris* and berberine as well as developmental toxicity and clinical studies. Data from the present study indicate that their toxicity is depending on the route and duration of administration. According to present study, they could induce GI upset and ulceration, immunotoxicity, phototoxicity, neurotoxicity, cardiotoxicity and jaundice in a dose dependent manner. They should be used with caution in pregnancy, neonatal and G6PD deficiency. Besides, consideration should be taken in co-administration of berberine with drugs that are metabolized with CYP enzymes due their inhibitory effects on these enzymes. Furthermore, they evoke cytotoxicity on both normal and cancer cell line which is time and concentration dependent.

**Keywords:** Acute toxicity, Berberine, *Berberis vulgaris*, Cancer cell, Chronic toxicity, CYP enzyme, Developmental toxicity, Pregnancy

**Introduction**

The genus *Berberis* with more than 500 species belongs to Berberidaceae family (1). *Berberis vulgaris* which is known as barberry, common or European barberry (2) is an evergreen shrub which possesses yellow, spiny, angled or sulcated bark, oblong, obovate, or elliptic leaves, yellow flowers and red, oblong fruits (3). It grows in Asia and Europe and is a well-known herb in Iran (4). The main isolated compounds from *B. vulgaris* are tannins, phenolic compounds, triterpenes (lupeol, oleanolic acid), sterols (stigmasterol, stigmasteryl glucoside) and alkaloids (berberamine, palmatine, berberine, oxyberberine, columbamine, isocorydine, lambertinea and magniflorine). Besides, bisbenzisouquinolines (oxycanthine), N-(p-trans- coumaroyl) tyramine, cannabisin G and (±)-lyoniresinol have been isolated from this plant (5).

Berberine, an isoquinoline alkaloid, is a member of naturally occurring protoberberines class (Figure 1). This alkaloid is present in plants of Berberidaceae, Papaveraceae and Ranunculaceae families including *Arcangelisia flava* (menispermaceae), *B. vulgaris* (barberry), *B. aristata* (tree turmeric), *B. aquifolium* (Oregon prape), *B. lyceum*, *B. craategina*, *Hydrastis canadensis* (goldenseal) and *Coptis chinensis* (Chinese goldthread). Berberine widely consumed in Ayurvedic and Chinese medicine. (4, 6, 7). Berberine has been isolated from various parts of these species such as root, stem, bark, fruit and rhizome (6).

Traditional use of root, bark, leaf and fruits of barberry as an immunemodulator and anti-microbial agent as well as a treatment for central nervous system, cardiovascular, gastrointestinal, endocrine, and renal problems have been proved with many pharmacological studies (4, 8). Recently published articles demonstrated that barberry and berberine (its main constituents) have anti-oxidant (9), anti-inflammatory (10), anti-tumor (11), anti-mutagenic (12) and anti-diabetic (9) effects. Their hypoglycemic and cholesterol lowering properties (13), neuroprotective (14), and hepatoprotective (15-17), effects have scientifically been proved by numerous studies. *B. vulgaris* may possesses preventive effects in relapse of morphine consumption in addicted individuals (18). It has been demonstrated that *B. vulgaris* and berberine induces inhibitory effects on Leishmania species (19-21). Also, it has been reported as an anti-fungal compound (20). There are evidences in *in vivo* and *in vitro* that berberine hydrochloride has beneficial effects on colitis (22).
Berberine could be absorbed from the gastrointestinal (GI) however; its oral bioavailability and its plasma level are very low. It should be noticed that berberine converted to ionized form in the physiological conditions and self-aggregated in low pH conditions. Self-aggregation decreases its solubility in the GI track and its permeability. The other barriers of berberine oral bioavailability are P-glycoprotein (P-gp) mediated efflux, hepatobiliary re-extraction and metabolization by CYP2D6 and CYP3A4 in the intestine (23). It has been shown that berberine is converted to dihydroberberine form by gut flora, which has higher intestine-absorbable rate in comparison berberine (24). Berberine is distributed in the liver, kidneys, muscle, lungs, brain, heart, pancreas and fat. Strikingly, tissue concentration of berberine and its metabolites is higher than plasma concentration (25). Berberine is metabolized in the liver by oxidative demethylation and glucuronidation to berberrubine (M1), thalifendine (M2), demethyleneberberine (M3), and jatrorrhizine (M4) and their glucuronide forms (Figure 1). CYP2D6, 1A2, 3A4, 2E1 and CYP2C19 are the main CYPs in berberine metabolisms (26). Finally, berberine metabolites are excreted through feces, urine, and bile (Figure 2). It is important to notice that there are some pharmacokinetic interactions in co-administration of berberine with metformin, ketoconazole, digoxin and cyclosporine A (8).

In spite of the panoramic use of barberry in different folklore as an herbal medicine, there is no comprehensive study which categorized the toxic effects of barberry in animal models and human studies. Hence, this review discusses on the toxic effects of barberry and berberine, as its main derivative, in terms of acute, sub-acute, sub-chronic, chronic toxicity with a mention on their developmental and mutagenic toxicity as evidenced from the scientific literature in animal and human assays.

Methods
A literature search was conducted and the available information on toxicology and pharmacological properties of *B. vulgaris* and berberine was collected via relevant keywords including *B. vulgaris*, barberry, berberine, acute toxicity, sub-acute toxicity, sub-chronic toxicity, chronic toxicity, mutagenic, developmental, miscarriage, cancer, and clinical trial in the following databases: PubMed, Scopus, Google Scholar and Web of Science. All kinds of relevant articles, abstracts or books were included. Furthermore, the reference lists of key papers for further leads were searched. No time limitation was considered in this review. Besides, no constraint was accounted about including all kinds of berberine containing herbs. Both *in vivo* and *in vitro* studies were included to this investigation. The toxic effects of barberry and berberine were categorized in following main headings: toxicological findings, developmental toxicity, cytotoxicity, genotoxicity, mutagenicity, carcinogenicity and clinical toxicity (Figure 3).

Toxicological findings
**Acute toxicity**
Acute toxicity test is the first toxicity assessment which is examined during 14 days and determined from the administration of a single exposure. It
estimates approximate lethal dose or concentration (e.g., LD$_{50}$ or LC$_{50}$) as an intrinsic toxicity of substance. The most often used species are mouse and rat (27).

*B. vulgaris* is moderately toxic. The oral LD$_{50}$ value for powdered root of *B. vulgaris* in mice is 2600 mg/kg (28). In “The Essential Guide to Herbal Safety”, according the former studies, the following LD$_{50}$ values have been reported: the oral LD$_{50}$ value for barberry root extract fraction 520 mg/kg (mice) and 1280 mg/kg (rats), for berberine 23 mg/kg (mice, IP) and for its sulphated form in oral administration have been reported >1 g/kg (rat) (29). Besides, in the earlier studies, the oral LD$_{50}$ values of berberine in mice was reported 329 mg/kg (30).

It has been found that berberine sulphate LD$_{50}$ value (isolated from *Berberis aristata*) after intraperitoneal administration in rats was 205 mg/kg. However, in 50 mg/kg, it evokes diarrhea in 4 out of 10 rats which has been attributed to its direct effects on the gastrointestinal track (31). In the early studies, oral LD$_{50}$ value of berberine sulfate in rats and mice was reported more than 1000 mg/kg and 329 mg/kg (32). Oral doses of 100 mg/kg berberine sulfate to cats induced vomiting for 6 to 8 hr followed by death of all animals 8 to 10 days, while it was well tolerated by rats. Following an oral administration of 2.75 g berberine (base or salt not stated) to dogs (weight unspecified) nausea, emesis, salivation, diarrhea, muscular tremor and paralysis appeared (33).

Acute toxicity of berberine hydrochloride in mice indicated the following LD$_{50}$ values: 9.0386 mg/kg (IV) and 57.6103 mg/kg (IP). However, berberine LD$_{50}$ value by intragastric administration couldn’t be evaluated which attributed to its low gastrointestinal absorption. Increasing berberine dosage from 20.8 to 41.6 g/kg (orally) evokes the elevation of berberine blood concentration from 0.168 µg/ml to 0.432 µg/ml and leads to 30% mortality rate. The safety dosage of berberine in oral administration in mice is 20.8 g/kg and in human would be 2.97 g/kg which is 100 times above the typical prescribed doses in clinical trials studies (34).

The oral LD$_{50}$ of isolated berberine from *Rhizoma coptidis* is 713.58 mg/kg in mice that is classified in slight toxicity rank (35, 36). The comparison of fibrous root of *Rhizoma coptidis* (FRC) with *Rhizoma coptidis* (RC) revealed LD$_{50}$ value of FRC and RC were greater than 7 and 4.89 g/kg in mice, respectively. Since no acute toxicity effect was observed with FRC, it classified in lowest toxicity class. The content of berberine in FRC and RC measured by HPLC was 1.20 and 5.61%, respectively. So, the lower toxicity effects of FRC can be attributed to lower content of its berberine (37).

In mice acute toxicity test, it has been shown that the mortality of berberine in 409, 512, 640, 800 and 1000 mg/kg, orally, is 10, 20, 40, 60, and 75%, separately (35).

Isoquinoline alkaloids from the roots of Turkish *Berberis* species manifested that administration of berberine in acute doses (200 mg/kg, orally) induces gastric lesions in 4 out of 6 mice which attributed to the inhibition of cyclooxygenese-2 transcription by berberine (38). Parallel to the consequences of acute toxicity, it has been revealed that berberine induces gastric damages dose dependently. After 24 hr of single therapy with berberine (104 and 209 mg/kg, orally) the ratio of ulceration were 1/6 and 3/6, respectively in mice. Mortality rate was 5/6 for 418 mg/kg while for 104 and 209 mg/kg there was no death (39).

The LD$_{50}$ values of *B. vulgaris* and berberine are summarized in Table 1.

**Sub-acute toxicity**

In sub-acute toxicity test (repeated-dose study) a special substance is administrated in 3 to 4 different dosages to the animals during one month or less and its biochemical and pathologic effects are evaluated following 14-28 days of exposure. Results of this study provide a good information about the toxicity of the substance after treatment with consecutive dosages and it offers a guideline to determine doses for sub-chronic studies (27).
Table 1. The median lethal dose (LD$_{50}$) values of barberry and berberine

| Compound                        | Animals | Route of administration | LD$_{50}$ value | Ref.     |
|---------------------------------|---------|-------------------------|-----------------|----------|
| B. vulgaris (powdered root)     | Mice    | Oral                    | 2600 mg/kg      | (28)     |
| B. vulgaris (root extract fraction) | Rat   | Oral                    | 1280 mg/kg      | (29)     |
|                                  | Mice    | IP                      | 520 mg/kg       | (29)     |
| Berberine                       | Mice    | Oral                    | 23 mg/kg        | (29)     |
| Berberine sulphate              | Rat     | Oral                    | > 1 g/kg        | (29)     |
| Berberine sulphate (Berberis aristata) | Rat | IP                      | 205 mg/kg       | (31)     |
| Berberine sulphate              | Rat     | IP                      | 1000 mg/kg      | (32)     |
|                                  | Mice    | Oral                    | 329 mg/kg       | (30)     |
| Berberine (rhizoma coptidis)    | Mice    | Oral                    | 713.58 mg/kg    | (35, 36) |
| Berberine hydrochloride         | Mice    | IV                      | 9.0386 mg/kg    | (34)     |
|                                  |         | IP                      | 57.6103 mg/kg   | (37)     |
| Rhizoma coptidis (fibrous root) | Mice    | Oral                    | > 7000 mg/kg    |          |

Oral sub-acute toxicity of derived alkaloids from the roots of Turkish Berberis species including berberine, berbemine, palmatine, oxyacanthine, magnoflorine and columbamine (25, 50 and 200 mg/kg) was evaluated in mice. The results showed that all alkaloids in 25 mg/kg for 7 days induces different degree of gastric ulcers (38). A sub-acute toxicity evaluation on the root extract of B. crataegina represented that in Freund’s complete adjuvant-induced chronic arthritis, administration of active ethanol, butanol, CHCl$_3$-ethanol and H$_2$O-I extract and fractions (300, 642, 472, 614 mg/kg, respectively) to rats for 21 days was safe without any toxicity and death. However, liver and kidney enlargement was observed with ethanol extract (21.3% and 9.7%, respectively), butanol fraction (14.6% and 4.2%, respectively) and CHCl$_3$-ethanol fraction (7.2% and 2.8%, respectively). Body weight was increased up to 30% with H$_2$O-I fraction, 27% with butanol fraction, 17.8% with ethanol extract and 11.3% with CHCl$_3$-ethanol fraction (39). Furthermore, it has been reported that intraperitoneal injection of berberine (10 and 20 mg/kg/day, for 1 week) decreases bilirubin protein binding in adult rats. Clinically it should be noticed that this substance could increase the risk of kernicterus in risky patients (36).

Mahmoudi et al (2016) in their study investigated the immunotoxic effects of the berberine (5 and 10 mg/kg/day, IP, for 14 days) in BALB/c mice. Administration of berberine (10 mg/kg) decreased spleen weight, blood cell count including the number of leucocytes, neutrophils and lymphocytes and diminished generation/differentiation of B- and T-cells and splenic CD19$^+$ B-cells, CD4$^+$ and CD8$^+$ T-cells. Totally, berberine in 10 mg/kg suppressed both cellular and humoral immune functions while in 5 mg/kg just influenced proliferation of lymphocytes and delayed-type hypersensitivity response (40).

Oral administration of berberine sulphate 50 or 100 mg/kg but not 25 mg/kg for 10 days to cats evoked hemorrhagic inflammatory problems in both small and large intestine (33).

Sub-chronic toxicity

The sub-chronic test occurring in repeatedly administration of a chemical for 30 to 90 days and its main goals are to determine “no observed adverse effect level” (NOAEL), “lowest observed adverse effect level” (LOAEL) and identifying the organs that are affected by chemical after consecutive administration. This type of study conducted in two
species (10-20 rodents and 4-6 dogs), orally, for at least 3 doses as follow: a low dose without toxic effects, a high dose that causes toxic effects with less than 10% fatalities and an intermediate dose. At the end of the 90th day, biochemical and hematological parameters, body weight, food consumption and other factors are measured (27).

Berberine is the main alkaloid in FRC. It has been shown that the extract of RC with 1.88 g/kg in Sprague Dawley rats has no adverse effects without any effects on blood biochemical factors. In 3.76 g/kg, damages to lung and liver have been reported where it increases alanine aminotransferase (ALT) and aspartate aminotransferase (AST), significantly (37). Another study indicated administration of RC alkaloids in 156 mg/kg, orally, for 90 days to Sprague Dawley rats has no poisoning symptoms, without any effects on the body weight and mortality (35).

**Chronic toxicity**

The duration of study in chronic test is longer than 90 days which depends on the species types. For example, chronic exposure in rodents is about 180 to 720 days and for non-rat rodent animals usually is 360 days or longer. The evaluation of maximum tolerable dose and the urinary metabolite indexes, carcinogenicity, physiological and pharmacokinetic aspects of chemicals are the main goal of the chronic toxicity studies (27).

The phototoxic effect of berberine concomitant with UVA radiation on mosquito larvae (*Aedes atropatus*) has been assessed. Larvae were treated with 10 ppm berberine in exposure to 0.4 W/m² UV for 24 hr, then they were transferred to the clean jars and observations were made to their adult stage during 4-week development. Berberine showed chronic toxicity and markedly increased cumulative mortality. The effects were further in pupil and adult stage. The underlying mechanism of berberine may be attributed to the production of singlet O₂ by bounded berberine to DNA (41).

Treating rats with 50 mg/kg berberine demonstrated that berberine has no obvious toxic effect on kidney and liver (13). Parallel to these results, in other study has been revealed that berberine at concentrations >50, 100 and 150 mg/kg after 16 weeks induces liver tissue damages in diabetic rats but not in healthy rats (42). In another study, chronic treatment with berberine (5 mg/kg/day for 15 weeks, IP) evoked atherosclerosis in apoE/- mice (43).

**Developmental toxicity**

Developmental toxicity is the study of adverse effects of a substance on the development of the organism resulting from exposure to chemical or physical agents pre-natal or post-natal until the time of puberty. Reproductive toxicity and teratogenicity also, assessed. Reproductive toxicity is a part of developmental toxicity, in which the adverse effects of the substances on male and female reproductive system are assessed. The substances that cause developmental toxicity from the time of conception till birth are called teratogen (27).

Administration of berberine (97.5 mg/kg/day, orally) and goldthread rhizome (0.6 g/kg/day, orally) to pregnant mice and rats (6th to 15th day of gestation) had no effects on induction of vaginal bleeding, abortion, neonates malformation and fetal toxicity (44). However, it has been reported that berberine evokes uterine contraction and could be a potent maternal toxic with teratogenic effects. The maternal LOAEL, developmental LOAEL and maternal NOAEL for mated rats treated with berberine chloride dehydrate during gestation period (day 6th to 20th) have been reported with doses 531, 1313 and 282 mg/kg/day, respectively (45).

Berberine chloride dehydrate administration to rats (282, 531 and 1313 mg/kg/day, orally) and mice (569, 841 and 1155 mg/kg/day, orally) reduces maternal weight and fetal body weight, respectively. The maternal toxicity LOAEL related is 7250 ppm (531 mg/kg/day) and 5250 ppm (841mg/kg/day) in rats and mice, respectively. One thousand mg/kg/day has been reported as the developmental toxicity NOAEL in rats and developmental toxicity LOAEL in mice (46). These levels would be lower for berberine chloride due the hydration in berberine chloride dehydrate (2).

Although plants rich in berberine traditionally has been used for the treatment of jaundiced neonates, recently it has been proved that berberine may induce jaundice and haemolysis in susceptible people. Bilirubin-displacing capacity of berberine has been proved recently. *In vitro* studies showed that berberine has displacement effects on the bilirubin from its binding sites on the human serum albumin. Furthermore, chronic administration of berberine to rats (10 and 20 µg/g, IP for 7 days) increased serum bilirubin concentration without any change in the total albumin concentration in the serum (47). Oral treatment or *in vitro* exposing of glucose-6-phosphate dehydrogenase (G6PD) deficient rat erythrocytes with excessively high doses of berberine increased the red blood cell osmotic fragilities and induced hemolysis (48). Nevertheless, there are records that demonstrated berberine did not induce jaundice and has no effects on G6PD performance during pregnancy (44, 49). Following administration of 200 mg/kg goldthread rhizome and 32.5 mg/kg berberine to neonate rats (subcutaneous), no effect on the G6PD activity and jaundice induction have been observed (44). Altogether, *B. vulgaris* and berberine-containing plants are organized in category C during pregnancy and should be avoided in lactation (2).
Cardiotoxicity

Some documents have mentioned on cardiotoxicity of berberine. Intravenous administration of berberine to dogs induced cardiac depression due to the dilation of splanchnic vessels (50). Also, the reduction of mitochondrial respiration and Ca^{2+} influx capacity has been reported (51). It has been shown that berberine induces inhibitory effects on L type voltage dependent Ca^{2+} channels but in higher concentration (100 µM) stimulates the release of Ca^{2+} from intracellular stores (52). Previous studies demonstrate that berberine (10-100 µM) can reversibly block human ether-a-go-go (hERG) channels in Xenopus oocytes (53) by directly binding to F656V (54). This inhibitory concentration was higher than the effective concentration in clinical application (53). The IC_{50} for berberine on hERG in HEK-293 cells and Xenopus oocytes has been reported 3.1±0.5 and 80±5 µM, respectively (55). Besides, it was shown that berberine by inhibition of inward rectifier potassium current, delayed rectifier potassium current and hERG channels increases the action potential which could have both anti-arrhythmic (53) and arrhythmogenic properties (54). Myotropic effects of B. vulgaris induces hypotensive effects (28).

Cytotoxicity, genotoxicity, mutagenicity, and carcinogenicity

Several studies have been reported that berberine has anti-tumor activity both in vitro and in vivo that could be mentioned as a worth anticancer drug. It decreases cell viability in different type of cancer cells such as nasopharyngeal (56), hepatocellular (57), breast (58), and cervical cancer cells (59) in a dose- and time-dependent manner. Berberine has some degree of toxicity in normal cells that its underlying mechanism is the inhibition of adenine nucleotide translocase followed by decrease in energy production (51). Treating cerebellar granule neurons (CGN) and hippocampal neurons (HCN) with berberine (10 nM to 10 mM) for 6 hr indicated that berberine at concentration less than 0.3 mM not only had no effects on the gross structure of axon and dendrite of CGN, but also in 0.1 mM could moderately increases cell viability. However, berberine in higher concentrations (more than 1mM) disturbs neural integrity and increases condensation of nuclei. Berberine in 10 mM induces the most toxic potential and after 2 hr from treatment, it increases oxidative stress and decreases neuronal viability (60).

It has been shown that berberine hydrochloride (extracted from RC) decreases proliferation, inhibits migration and induces apoptosis in CNE-1 nasopharyngeal carcinoma cells in a time- and dose-dependent manner. Treating CNE-1 cells with berberine hydrochloride for 48 hr inhibits invasion and migration (10 µg/ml) and their cell growth (40 µg/ml) by activating apoptosis pathway (56).

Other study proved the anti-cancer effects of berberine on MCF-7 and MDA-MB-231 breast cancer cells. The results have indicated that treating MCF-7 and MDA-MB-231 cells by berberine (10 to 100 µM for 48 or 72 hr) inhibits cell viability in a dose and time-dependent manner. The morphology of MCF-7 and MDA-MB-231 cells is changed in response to berberine (50 µM). Besides, treating with berberine, for 24-72 hr, elevates the ratio of apoptotic proteins and caspase-3 activity. This cytotoxicity has been attributed to reactive oxygen species (ROS) formation. It has been shown that berberine with 50 µM increases the ROS production after 6 hr (58). It has been suggested that apoptosis and specially necrosis play a main role in berberine-induced cytotoxicity on prostate cancer LNCaP cells, too (61).

Parallel to the consequences mentioned above, it has been reported that berberine at the concentration of 20 µM significantly inhibits the invasion ability of cervical cancer cells and decreases their motility (59). The IC_{50} values of berberine in the HL-7702 normal hepatic cells is 838.4 µM whereas in HepG2, SMMC-7721 and Bel-7402 cells are 34.5 µM, 25.2 µM and 53.6 µM, respectively (57). Acute cytotoxicity of berberine on Ehrlich ascites carcinoma (EAC) cells has been observed in 10 µg/ml that markedly induces apoptosis and in 50 and 100 µg/ml that suppresses DNA synthesis, changes the structure of dsDNA and induces death. The IC_{50} value of berberine on EAC cells has been reported less than 1 µg/ml (62).

Berberine has cytotoxicity effects on L929 Murine Fibroblast cells. Berberine in the concentrations from 0.0025 mg/ml to 0.025 mg/ml has no cytotoxic effects, whereas DNA damages in concentration more than 0.025 mg/ml has been observed. Berberine in concentrations higher than 0.1 mg/ml changes the structure of L929 cells and induces ROS formation and apoptosis. Cytotoxic effects of berberine significantly manifests when these cells are treated with 0.2 mg/ml (63). The morphology of C6 rat glioma cells is altered after treating with berberine (>50 µM). Besides, this alkaloid induces cell death in a time- and dose-dependent manner. Following treatment with berberine (100 µM, for 12, 24, 48 and 72 hr), G2/M cell cycle phases are arrested and significantly apoptotic cell death is observed when it promotes the activity of caspase-3, -8 and -9 time-dependently (64). Berberine iodide and acetoneberberine are more toxic against human oral squamous cell carcinoma and human promyelocytic leukemia than against normal human oral tissue-driven cells. Respectively, the IC_{50} values on HL-60 have been reported 18, 22 µM, on HSC-2, HSC-3, HSC-4 and NA cells 47, 88 µM, and on CA9-22 cells 132, 136 µM, where for HGF >400, 293 µM, HPC 235, 219 µM and HPLF 245, 189 µM (65).
The effect of *Berberis vulgaris* or berberine on normal and cancer cell line under *in vitro* conditions

| Type                          | Dose                              | Toxic responses                                                                 | Ref. |
|-------------------------------|-----------------------------------|---------------------------------------------------------------------------------|------|
| Normal                        |                                   |                                                                                 |      |
| HUVEC cells                   | Berberine: 40 µM                  | Decreased the cell viability by 87.6%                                           | (59) |
| L929                          | Berberine: 2.5-200 µg/mL          | Did not show any cytotoxic effects (at 2.5 µg/ml to 25 µg/ml)                  | (63) |
| Gingival fibroblast HGF, pulp cell HPC, periodontal ligament fibroblast HPLF | Berberine iodide and acetoneberberine: 10, 20 and 80 µM | Tumor-specific cytotoxic effect of berberine iodide and acetoneberberine that IC50 values in HGF, HPC and HPLF were >400, 293, 235, 219; and 245, 189 µM, respectively | (65) |
| HEK293                        | Berberine: 0-100 µM               | Did not show any growth inhibitory effect                                       | (66) |
| Normal human prostate epithelial PWR-1E cells | Berberine: 5-50 µM               | NO growth inhibition in normal prostate cells observed                            | (67) |
| L929                          | Berberine hydrochloride: 10-100 µg/ml | In a concentration-dependent manner berberine induced cytotoxic effects (IC50: 40 µg/ml) | (68) |
| Cancerous                     |                                   |                                                                                 |      |
| CNE-1                         | Berberine hydrochloride: 2.5, 5, 10, 20 and 40 µg/ml | Decreased Cell viability Activated caspase-3, decreased twist protein levels and increased apoptotic proteins Inhibited migration and invasion of cells | (56) |
| HepG2, SMMC-7721 and Bel-7402 | Berberine: 3.125, 6.25, 12.5, 25, 50 and 100 µM | Decreased the cell viability in a time- and dose-dependent manner (the IC50 value in HepG2, SMMC-7721 and Bel-7402: 34.5 µM, 25.5 µM and 53.6 µM, respectively) | (57) |
| MCF-7 and MDA-MB-231          | Berberine: 10–100 µM              | Dose- and time dependent inhibitory effect Increased apoptotic ratio, caspase-3 activity and alteration in cell morphology Increased the ROS generation and accumulation | (58) |
| CsSki, SiHa, and HeLa         | Berberine: 20 µM                  | In a dose-dependent manner, inhibited the invasion of CsSki, HeLa and SiHa cells Inhibited the migration of CsSki, SiHa, and HeLa cells Decreased the SiHa cell motility | (59) |
| LNGaP and PC-82               | Berberine: 1-100 µM               | Dose-dependently decreased the cell viability and induced programmed necrosis and apoptosis | (61) |
| EAC                           | Berberine: 10, 50 and 100 µg/ml   | Increased apoptotic cells (at 10 µg/ml) Inhibited DNA synthesis, changed the morphology of dsDNA and induced cell death (at 50 and 100 µg/ml) (IC50 below 1 µg/ml) | (62) |
| C6 rat glioma                 | Berberine: 100µM                 | In a time- and dose-dependent manner, altered the cell morphology, promoted the caspase-3, -8 and -9 activity, increased the production of ROS and induced apoptotic cell death | (64) |
| Human oral squamous cell carcinoma: HSC-2, HSC-3, HSC-4, NA, CA9-22 and human promyelocytic leukemia: HL-60 | Berberine iodide and acetoneberberine: 10, 20 and 80 µM | Increased apoptotic cells, DNA fragmentation, caspase-3, -8 and -9 and pro-apoptotic BAD protein. [did not elevate BAD protein in HSC-2 cells] IC50 for Berberine iodide and acetoneberberine in sequence: HL-60 (18, 22 µM), HSC-2 (59, 65 µM), HSC-3 (83, 47 µM), HSC-4 (54, 69 µM) and NA (88, 53 µM) and CA 9-22 cells (136, 132 µM) | (65) |
| HCT116, SW480 and LOVO colorectal carcinoma cells | Berberine: 0-100 µM for 24,48 and 72 hr | In a concentration- and time-dependent manner, inhibited the growth of cancer cells via programmed death | (66) |
Several lines of evidences have been conducted on the effect of berberine in normal and cancerous cells in vivo. Li and colleagues (2015) in their study evaluated the effect of berberine on aoxymethane and dextran sulfate sodium (AOM/DSS) promoted colorectal carcinogenesis mouse model. They observed a reduction in tumor multiplicity when 40 mg/kg of berberine was given to mice for 10 weeks (66). In the other study SiHs cells were injected subcutaneously or into tail vein of mice for evaluating the effects of berberine (20 mg/kg/day, oral) on the tumor growth and lung metastasis, respectively. According gathered data, berberine treatment decreased tumor size and angiogenesis. Besides, it reduced pulmonary weight and lung metastasis (59). In murine 4T1 breast cancer model, berberine moderately inhibited growth and weight of tumor. Its combination with anti-DR5 increased synergically their anti-tumor effects and reduced the incidence of lung metastatic (73). Furthermore, the growth and weight of tumors that were induced by implantation of S 180 sarcoma tumor cells to Kunming mice (74), prostate cancer PC-3 and LNCaP cells to BALB/c athymic nude mice (67), Lewis lung carcinoma cell line (LLC) to C57BL/6 mice (69) and Dalton’s lymphoma ascites cells (DLA) to Swiss albino mice (68) were inhibited by berberin treatment. However, berberine but not NAX014 compounds (berberine derivatives) had no suppressive effects in spontaneous mammary tumors in HER-2/neu transgenic mice (75).

The effects of B. vulgaris or berberine on normal and cancer cell line under in vitro and in vivo conditions are summarized in Tables 2 and 3, respectively.

According to chromosomal aberration analysis, berberine stimulates double strand breaks in Rev3 deficient cells (76). The comet assay test shows that berberine and goldenseal (rich in berberine) induces DNA damage in HeLa cells (77) and HepG2 cells by inhibition of topoisomerase 1 in a dose and time dependent manner (78). This DNA damage is accompanied with increasing the level of histone H2AX phosphorylation at Serine139 (γ-H2AX), cell cycle arrest and activating checkpoints related protein (78). Former, SOS chromo test has been reported negative for berberine chloride. It had no mutagenic effects (induction of frameshift, point mutation and cytoplasmatic PETITE mutation) in haploid yeast cells under nongrowth conditions, but in dividing cells elevated the frequency of HOM3 frameshift revertants and cytoplasmatic PETITE mutation, dose dependently. Furthermore, berberine treatment increased induction of crossing over in diploid yeast cells during growth condition but not in nongrowth cells (79). Recently, it has been reported that berberine, time and concentration dependently, evokes oxidative stress and DNA damage both in mouse marrow cells (80) and mouse heart cells (81). In Ames test, berberine hydrochloride was weakly mutagenic to strain TA98 (82), but no mutagenic activity of tetrahydroberberine (82) and FRC has
Table 3. The effect of *Berberis vulgaris* or berberine on cancer cell line under *in vivo* conditions

| Type                                      | Dose                          | Toxic responses                                                                 | Ref. |
|-------------------------------------------|-------------------------------|---------------------------------------------------------------------------------|------|
| SiHa treated                              | Berberine 20 mg/kg            | Reduced angiogenesis, tumor growth properties and pulmonary colonization of SiHa cells | (59) |
| Azoxymethane initiated and               | Berberine: 40 mg/kg, orally, | Berberine reduced tumor multiplicity compared with control group and significantly decreased COX-2 synthesis | (66) |
| dextran sulfate sodium promoted           | mice, for 10 weeks           |                                                                                  |      |
| colorectal carcinogenesis                  | Berberine: 5, 10 mg/kg, IP,  | Tumor size and growth was decreased                                             | (67) |
| Prostate cancer PC-3 and LNCaP cells      | for 4 weeks twice per week   |                                                                                  |      |
| DLA cells to induce ascites tumour        | Berberine hydrochloride (10, | Increased life span and reduced tumour size                                    | (68) |
| and solid tumour, separately              | 2.5 and 0.5 mg/kg/day), IP   |                                                                                  |      |
|                                           | for 10 days                   |                                                                                  |      |
| LLC                                       | Berberine hydrochloride (25, | Berberine with infrared radiation significantly decreased tumor volume          | (69) |
|                                           | 5 and 1 mg/kg, orally for 10 | Berberine treatment alone has promising effects on suppressing tumor growth      |      |
| days                                      |                               |                                                                                  |      |
| 4T1 treated                               | Berberine chloride n-        | Moderately inhibited tumor growth in 4T1 cells                                   | (73) |
|                                           | hydrate: 100 mg/kg/day,      |                                                                                  |      |
|                                           | Orally, one month            |                                                                                  |      |
| Murine sarcoma S180                       | Berberine 30 mg/kg, IV       | Decreased tumor weight                                                          | (74) |

been observed in histidine-requiring *Salmonella typhimurium* mutant strains (37). Besides, mouse micronucleus test and mouse sperm abnormality test was negative for FRC (37).

Phototoxicity could be considered as genotoxicity of berberine. The use of berberine in eye drops and lotions results ocular photodamage and raises the possibility of lens epithelial cells disorders (83). Berberine (50 μM) in exposure to UVA radiation causes cell death in human HaCaT keratinocytes (80% decrease in cell viability) and DNA damage in the form of single strand breaks. Also, the berberine phototoxicity is interestingly dependent on its solvent. Radiation of berberine generates both O₂ and radical species in nonpolar solvents such as CH₃Cl₂ but not in aqueous solutions. UVA protection should be considered when berberine topical preparation is used (84).

**Clinical toxicity**

In a clinical study, 34.5% patients with type-2 diabetes that treated with berberine (500 mg three times/day) for 13 weeks have shown transient GI side effects diarrhea, constipation, flatulence and abdominal complaint. However, no obvious change in liver enzymes and creatinine was observed (85).

Infusion of berberine, 0.2 mg/kg/min for 30 min, in patients (n=12) with refractory cardiac heart failure improved cardiac performance probably due to peripheral vasodilator and inotropic effects. However, in 4 patients 1-20 hr after the infusion of berberine ventricular tachycardia with torsade de pointes appeared (86).

There are evidences that revealed berberine could cause kernicterus in infants with G6PD deficiency (87) and the bilirubin displacement from binding proteins (88). Numerous endogenous and exogenous substances by interfering with the binding of bilirubin to albumin may cause the risk of jaundice. In a clinical study, administration of RC and *Cortex phellodendri* (chinese herbs containing berberine) 3 and 9 g/day, respectively for 24 weeks to 3 thalasemic patients, increased bilirubin in serum (89). It is proposed that berberine usage should be avoided in pregnancy, breastfeeding period and G6PD deficient neonates (5, 87). Nevertheless, in a cohort study, the extract of RC and *Cphellodendri* (rich in berberine) were administrated to chronic cytopenic haematologic patients for 24 weeks. The results illuminated that berberine was safe without any clinical deterioration and influence in creatinine level and liver function (89).

**The effects on CYP enzymes**

An important subject for notification is the effects of *B. vulgaris* and berberine on the CYP enzymes that is important in coadministration with narrow therapeutic index drugs such as cyclosporine (54). Evaluation of berberine IC₅₀ values for CYPs and its constituents may be useful for prediction of possible herb–drug interactions which may have either positive or negative therapeutic effects. The effect of berberine on these enzymes are summarized in Table 4.
Table 4. Berberine IC<sub>50</sub> values for cytochrome P450 enzymes (CYPs)

| Type of CYPs | Model                      | Berberine IC<sub>50</sub>          | Ref. |
|--------------|----------------------------|-----------------------------------|------|
| CYP1A1       | A recombinant enzyme system| 1.38 ± 0.12 µM                    | (90) |
|              | HepG2 cells                | 2.5 µM                            | (91) |
| CYP1A2       | A recombinant enzyme system| 60 µM<                            | (90) |
|              | CYP1A2 over expressing Huh-7 cells | 10 µM                  | (92) |
|              | Human liver microsomes     | >100 µM                           | (93) |
|              | Supersomes system          | 73.2 ± 5.5 µM< (higher than human blood concentration) | (94) |
| CYP3A4       | Human liver microsomes     | >100 µM                           | (93) |
|              | Supersomal system          | 48.9 ± 9 µM                      | (94) |
|              | Human liver microsomes     | 400 µM                            | (95) |
| CYP1B1       | A recombinant enzyme system| 94 ± 8 nM (possible potential for clinical inhibition) | (90) |
| CYP2C9       | Human liver microsomes     | >100 µM                           | (93) |
| CYP2C8       | Human liver microsomes     | >100 µM                           | (93) |
| CYP2C19      | Human liver microsomes     | >100 µM                           | (93) |
| CYP2D6       | Human liver microsomes     | 49.4 µM                           | (93) |
|              | Supersomal system          | 7.40 ± 0.36 µM (possible potential for clinical inhibition) | (94) |
|              | Human liver microsomes     | 45 µM                             | (95) |

In a two-phase randomized-crossover clinical study on 70 healthy Chinese male volunteers [(mean±SD) age, 21.6 ±1.5 years; weight, 61.35±3.89 kg], the effect of berberine on CYP enzymes activities in vivo were accessed. Midazolam, omeprazole, dextromethorphan, losartan, and caffeine were used as CYP450 probe drugs to evaluate enzyme activities of CYP3A4, 2C19, 2D6, 2C9, and CYP1A2. According to data, repeated administration of berberine (300 mg, T.I.D., orally, 2 weeks) to volunteers decreased CYP2D6, 2C9, and 3A4 activities (96).

Figure 4. Schematic diagram showing toxic effects of Berberis vulgaris and berberine in different animal toxicity tests.
In another randomized, controlled clinical trial two groups of renal transplant patients on cyclosporine A were included. Berberine treated group: 52 renal transplant recipients both male and female (31/21) volunteers [(mean±SD) age: 42.5 ±10.8 years; weight: 55.3±10.2 kg] that received cyclosporine A (319.2±90.7 mg/day), azathioprine (43.4±17.4 mg/day), prednisone (12±4.1 mg/day) and berberine hydrochloride tablets orally (200 mg t.i.d.) for 3 months and berberine free group: 52 renal transplant recipients both male and female (40/12) volunteers [(mean±SD) age: 39.6±11.9 years; weight: 56.9±8.5 kg] that received cyclosporine A (309.3±62.9 mg/day), azathioprine (47.3±5.3 mg/day) and prednisone (12.4±4.1 mg/day). This study showed that berberine markedly increases the blood concentration of cyclosporine A in renal-transplant recipients which could be attributed to inhibition of CYP3A4 by berberine in the liver and/or small intestine (97).

**Conclusion**

Huge numbers of published articles on the medicinal worth of barberry and its constituents have shown that they have a great potential to develop as a useful drug especially in the area of cancer, cardiovascular and metabolic disorders. However, till now no drug has been introduced in the market using pure barberry, berberine or the other barberry components. This might be resulted from low clinical data. Certain information about barberry/its main secondary metabolites toxicity needs to be addressed before they can be used as approved therapeutic drugs in human.

In the present study, we summarized a variety of scientific articles that evaluated the toxicity of B. vulgaris and berberine. By considering the LD50 values, it is clear that their toxicity depends on the experimental animal species, dose and route of administration as well as the herb source. The risk of toxicity in oral route is less than IP and IV injections.

Results in animal and in vitro studies have proved the potential of berberine to induce GI upset and ulceration, immunotoxicity, phototoxicity, neurotoxicity and cardiotoxicity in a dose dependent manner (Figure 4). Besides, there are controversial data in using berberine and its derivative during pregnancy, so the use of them should be cautioned in pregnancy and neonatal. Berberine by inhibiting adenine nucleotide translocase, promoting ROS formation, apoptosis and necrosis pathways induces its toxicity on both normal and cancer cell in a time and concentration dependent manner. Finally, the inhibitory effects of berberine on CYP enzymes should be mentioned which could evoke indirect toxicity. This interaction is important in co-administration with narrow therapeutic index drugs which may increase the drug plasma concentration and toxicity.

Nevertheless, as mentioned, these data mostly have been gathered from animal studies and there are differences between animals and human body, so more clinical studies in future could reveal the concealed toxicity of berberine and its derivatives.

**References**

1. Rounsaville TJ, Ranney TG. Ploidy levels and genome sizes of Berberis L. and Mahonia Nutt. species, hybrids, and cultivars. HortScience 2010;45:1029-1033.
2. Bone K, Mills S. Materia medica. Principles and practice of phytotherapy modern herbal medicine. 2st ed. USA: Churchill livingstone; 2013. p. 399-418.
3. Ahrendt LWA. Berberis and Mahonia: a taxonomic revision. Bot J Linn Soc 1961;57:1-410.
4. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res 2008;22:999-1012.
5. Mokhr-Dezfuli N, Saednia S, Gohari A, Kurepaz-Mahmoodabadi M. Phytochemistry and pharmacology of Berberis species. Pharmacogn Rev 2014;8:8-15.
6. Singh IP, Mahajan S. Berberine and its derivatives: a patent review (2009 - 2012). Expert Opin Ther Pat 2013;23:215-231.
7. Smolinske SC. Herbal product contamination and toxicity. J Pharm Pract 2005;18:188-208.
8. Imenshahidi M, Hosseinzadeh H. Berberis Vulgaris and berberine: an update review. Phytother Res 2016;30:1745-1764.
9. Abd El-Wahab AE, Ghareeb DA, Sarhan EE, Abu-Serie MM, El Demellawy MA. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med 2013;13:218-229.
10. Lin K, Liu S, Shen Y, Li Q. Berberine attenuates cigarette smoke-induced acute lung inflammation. Inflammation 2013;36:1079-1086.
11. Yu FS, Yang JS, Lin HJ, Yu CS, Tan TW, Lin YT, et al. Berberine inhibits WEHI-3 leukemia cells in vivo. In Vivo 2007;21:407-412.
12. Cernakova M, Kos’alova D, Kettmann V, Plodova M, Toth J, Drimal J. Potential antimutagenic activity of berberine, a constituent of Mahonia aquifolium. BMC Complement Altern Med 2002;2:2.
13. Jiang Z, Liu F, Ong ES, Li SPY. Metabolic profile associated with glucose and cholesterol lowering effects of berberine in Sprague-Dawley rats. Metabolomics 2012;8:1052-1068.
14. Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2011;25:43-17-32.
15. Domitrovic R, Jakovac H, Blagojevic G. Hepatoprotective activity of berberine is mediated by inhibition of TNF-a, COX-2, and iNOS expression in CCI(4)-intoxicated mice. Toxicology 2011;280:33-43.
16. Feng Y, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, et al. Hepatoprotective effects of berberine on carbon.
tetrahydrocannabinol-induced acute hepatotoxicity in rats. Chin Med 2010;5:33.
17. Hermenean A PC, Ardelean A, Stan M, Hadaruga N, Mihali CV, Costache M, Dinischiotu A. Hepatoprotective effects of Berberis vulgaris L. extract/β cyclodextrin on carbon tetrachloride-induced acute toxicity in mice. Int J Mol Sci 2012;13:9014-9034.
18. Imenshahidi M, Qaredashi R, Hashemzaei M, Hosseinzadeh H. Inhibitory effect of Berberis vulgaris aqueous extract on acquisition and reinstatement effects of morphine in conditioned place preferences (CPP) in mice. Jundishapur J Nat Pharm Prod 2014;9:e16145.
19. Mahmoudvand H, Sharirifar F, Sharirif I, Ezatpour B, Fasibi Harandi M, Makki MS, et al. In vitro Inhibitory effect of Berberis vulgaris (berberidaceae) and its main component, berberine against different leishmania species. Iran J Parasitol 2014;9:28-36.
20. Mahmoudvand H, Ayatollahi Mousavi SA, Sepahvand A, Sharirifar F, Ezatpour B, Gorohi F, et al. Antiinflugal, antiileamental, and cytotoxicity activities of various extracts of Berberis vulgaris (berberidaceae) and its active principle berberine. ISRN Pharmacol 2014;2014.
21. Salehabadi A KM, Farzad MH, Namaei MH. Effect of root bark extract of Berberis vulgaris L on leishmania major on BALB/c mice. Parasitol Res 2014;113:953-957.
22. Minaiyan M, Ghannadi A, Mahzouni P, Jaffari-Shirazi E. Comparative study of Berberis vulgaris fruit extract and berberine chloride effects on acetic acid-induced colitis in rats. Iran J Pharm Res 2011;9:7-104.
23. Liu CS, Zheng YR, Zhang YF, Long XY. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia 2016;109:274-282.
24. Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep 2015;5:12155.
25. Li J, Zhang J, Feng R, Ma C, Chen WJ, Sun YP, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PloS One 2013;8.
26. Guo Y, Li F, Ma X, Cheng X, Zhou H, Klaassen CD. CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica 2011;41:996-1005.
27. Eaton DL, Gilbert SG. Principles of Toxicology. In: D.Klasssen C, editor. Casarett & Doull’s Toxicology the basic science of poisons. 8st ed. New York: MC Grow Hi education; 2013. p. 34-37.
28. Peychev L. Pharmacological investigation on the cardiovascular effects of Berberis vulgaris on tested animal. Pharmacia 2005;52:118-121.
29. Morgan M, Bone K, Mills S, McMillan J. Safety monographs. In: Mills S, Bone K, editors. The Essential Guide to Herbal Safety. USA: Elsevier Health Sciences; 2005. p. 255-261.
30. Haginawa J, Harada M. Pharmacological studies on crude drugs. V. Comparison of berberine type alkaloid-containing plants on their components and several pharmacological actions. Yakugaku Zasshi 1962;82:726-731.
31. Kulkarni SK, Dandiya PC, Varandani NL. Pharmacological investigations of berberine sulphate. Jpn J Pharmacol 1972;22:11-16.
32. Gardner Z, McGuffin M. American Herbal Products Association’s Botanical Safety Handbook. 2nd ed. New York: CRC Press; 2013.p. 130-132.
33. Lampe KF. Berberine. In: Smet PAGMD, K.Keller, R.Hansel, R.F.Chandler, editors. Adverse effects of herbal drugs. 1. New York: Springer-Verlag; 1992. p. 97-104.
34. Kheir MM, Wang Y, Hua L, Hu J, Li L, Lei F, et al. Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem Toxicol 2010;48:1105-1110.
35. Yi J, Ye X, Wang D, He K, Yang Y, Liu X, et al. Safety evaluation of main alkaloids from rhizoma coptidis. J Ethnopharmacol 2013;145:303-310.
36. Ho CE, Goh YL, Zhang C. From prejudice to evidence: the case of rhizoma coptidis in singapore. Evid Based Complement Alternat Med 2014;2014:71720:25.
37. Ning N, Wang YZ, Zou YZ, Zhang DZ, Wang DZ, Li XG. Pharmacological and safety evaluation of fibrous root of rhizoma coptidis. Environ Toxicol Pharmacol 2015;39:53-69.
38. Kupeli E, Kosar M, Yesilada E, Husnu K, Baser C. A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of turkish berberis species. Life Sci 2002;72:645-657.
39. Yesilada E, Kupeli E. Berberis crataegina DC. root exhibits potent anti-inflammatory, analgesic and febrifuge effects in mice and rats. J Ethnopharmacol 2002;79:237-248.
40. Mahmoudzadeh M, Zamanitaghiadae Rabe S, Balalimood M, Karimi G, Memar B, Rahnama M, et al. Immunotoxicity induced in mice by subacute exposure to berberine. J Immunotoxicol 2016;13:255-262.
41. Philogene BJ, Arnason JT, Towers GH, Abramowski Z, Campos F, Champagne D, et al. Berberine: a naturally occurring phototoxic alkaloid. J Chem Ecol 1984;10:115-123.
42. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, et al. Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 2008;31:1169-1176.
43. Li K, Yao W, Zheng X, Liao K. Berberine promotes the development of atherosclerosis and foam cell formation by inducing scavenger receptor A expression in macrophage. Cell Res 2009;19:1006-1017.
44. Shouye Y, Xuhua W. A research on the erupted fetal diseases caused by traditional Chinese drugs—discussion from the issue that chinese goldthread rhizome is prohibited in Singapore. J Tradit Chin Med 2008;28:235-240.
45. Bone K. Berberine-containing herbs and pregnancy. Townsend Letter: The Examiner of Alternative Medicine 2007:59-61.
46. Jahkke GD, Price CJ, Marr MC, Myers CB, George JD. Developmental toxicity evaluation of berberine in rats and mice. Birth Defects Res B Dev Reprod Toxicol 2006;77:195-206.

47. Chan E. Displacement of bilirubin from albumin by berberine. Neonatology 1993;63:201-208.

48. Lin N, Gao X, Li J, Zhu J. Influence of huanglian and berberine on the erythrocytic osmotic fragilitas of experimental glucose-6-phosphate dehydrogenase deficiency in rats. Zhongguo Zhong Yao Za Zhi 1998;23:562-564.

49. Chen C YZ, Li Y, Fichna J, Storr M. Effects of berberine in the gastrointestinal tract—a review of actions and therapeutic implications. Am J Chin Med 2014;42:1053-1070.

50. Chopra RN IC. Indigenous Drugs of India. Calcutta: Academic Publishers; 1933. p. 294.

51. Pereira CV, Machado NG, Oliveira PJ. Mechanisms of berberine [natural yellow 18]-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol Sci 2008;105:408-417.

52. Dong D, Sun J, Luo D, Chen Q, Wang F, He S, et al. Effect of berberine on the cytosolic calcium concentration in the single ventricular cell of guinea pig. Chin J Pharm Toxicol 2000;14:128-130.

53. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. Acta Pharmacol Sin 2001;22:125-131.

54. Zhi D, Peng PF, Sun JL, Guo F, Zhang R, Zhao X, et al. The enhancement of cardiac toxicity by concomitant administration of berberine and macrolides. Eur J Pharm Sci 2015;76:149-155.

55. Rodriguez-Menchaca A, Ferrer-Villada T, Lara J, Fernandez D, Navarro-Polanco RA, Sanchez-Chapula JA. Block of HERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J Cardiovasc Pharmacol 2006;47:21-29.

56. Li CH, Wu DF, Ding H, Zhao Y, Zhou KY, Xu DF. Berberine hydrochloride impact on physiological processes and modulation of twist levels in nasopharyngeal carcinoma CNE-1 cells. Asian Pac J Cancer Prev 2014;15:1851-1857.

57. Yang X, Huang N. Berberine induces selective apoptosis through the AMPK-mediated mitochondrial/caspase pathway in hepatocellular carcinoma. Mol Med Rep 2013;8:505-510.

58. Xie J, Xu Y, Huang X, Chen Y, Fu J, Xi M, et al. Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. Tumour Biol 2015;36:1279-1288.

59. Chu SC, Yu CC, Hsu LS, Chen KS, Su MY, Chen PN. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol 2014;86:609-623.

60. Kyesnus K, Brunello CA, Huttenen HJ. Mitochondria and NMDA receptor-dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One 2014;9:e107129.

61. Zhang LY, Wu YL, Gao XH, Guo F. Mitochondrial protein cyclinophilin-D-mediated programmed necrosis attributes to berberine-induced cytotoxicity in cultured prostate cancer cells. Biochem Biophys Res Commun 2014;450:697-703.

62. Letasiova S, Jantova S, Miko M, Ovadekova R, Horvathova M. Effect of berberine on proliferation, biosynthesis of macromolecules, cell cycle and induction of intercalation with DNA, dsDNA damage and apoptosis in Ehrlich ascites carcinoma cells. J Pharm Pharmacol 2006;58:263-270.

63. Gu M, Xu J, Han C, Kang Y, Liu T, He Y, et al. Effects of berberine on cell cycle, DNA reactive oxygen species, and apoptosis in 1929 murine fibroblast cells. Evid Based Complement Alternat Med 2015;2015:96306:13.

64. Chen TC, Lai KC, Yang JS, Liao CL, Hsia TC, Chen GW, et al. Involvement of reactive oxygen species and caspase-dependent pathway in berberine-induced cell cycle arrest and apoptosis in C6 rat glioma cells. Int J Oncol 2009;34:1681-1690.

65. Inoue K, Kulsam U, Chowdhury SA, Fujisawa S, Ishihara M, Yokoe I, et al. Tumor-specific cytotoxicity and apoptosis-inducing activity of berberines. Anticancer Res 2005;25:4053-4059.

66. Li W, Hua B, Saud SM, Lin H, Hou W, Matter MS, et al. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog 2015;54:1096-1109.

67. Choi MS, Oh JH, Kim SM, Jung HY, Yoo HS, Lee YM, et al. Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int J Oncol 2009;34:1221-1230.

68. Anis K, Kuttan G, Kuttan R. Role of berberine as an adjuvant response modifier during tumour therapy in mice. J Pharm Pharmacol 1999;51:697-700.

69. Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys 2008;70:5:29-54.

70. Iizuka N, Miyamoto K, Hazama S, Yoshino S, Yoshimura K, Okita K, et al. Anticachectic effects of berberine, an anti-inflammatory herb, on esophageal cancer cells that produce interleukin 6. Cancer Lett 2000;158:1070-1076.

71. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004;203:127-137.

72. Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, Perkins EL, et al. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dimethoxybenzo[g]1,3-benzodioxolo[5,6-a]quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmaco Exp Ther 2007;323:636-649.

73. Refaat A, Abdelhamed S, Yagita H, Inoue H, Yokoyama S, Hayakawa Y, et al. Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer. Oncol Lett 2013;6:840-844.

74. Zhang L, Li J, Ma F, Yao S, Li N, Wang J, et al. Synthesis and cytotoxicity evaluation of 13-n-alkyl...
berberine and palmatine analogues as anticancer agents. Molecules 2012;17:11294-11302.
75. Pierpaoli E, Damiani E, Orlando F, Lucarini G, Bartozzi B, Lombardi P, et al. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. Carcinogenesis 2015;36:1169-1179.
76. Hu X, Wu X, Huang Y, Tong Q, Takeda S, Qing Y. Berberine induces double-strand DNA breaks in Rev3 deficient cells. Mol Med Rep 2014;9:1883-1888.
77. Jageta GC, Rao. Isoquinoline alkaloid berberine exerts its antineoplastic activity by inducing molecular DNA damage in hela cells: a comet assay study. Biol Med 2015;7:223.
78. Chen S, Wan L, Couch L, Lin H, Li Y, Dobrovolsky VN, et al. Mechanism study of goldenseal-associated DNA damage. Toxicol Lett 2013;221:64-72.
79. Pasqual MS, Lauer CP, Moyna P, Henriques JAP. Genotoxicity of the isoquinoline alkaloid berberine in prokaryotic and eukaryotic organisms. Mutat Res 1999;286:243-252.
80. Xu C, Wang L, Hui X, Ma X, Ma F, Zhao Q, et al. DNA damage and effects on antioxidative enzymes in mouse marrow induced by berberine. 2013 International Conference on Human Health and Medical Engineering; China: WIT Transactions on Biomedicine and Health; 2014. p. 479-486.
81. Xu CB, Wang L, Hui XJ, Ma XP, Bi X, Zhao Q. Genetic toxicity of berberine on mouse heart. 2013 3rd International Conference on Biotechnology, Chemical and Materials Engineering; China: Adv Mat Res; 2014. p. 634-637.
82. Nozaka T, Watanabe F, Tadaki Si, Ishino M, Morimoto K, Kunitomo Ji, et al. Mutagenicity of isoquinoline alkaloids, especially of the aporphine type. Mutat Res 1990;240:267-279.
83. Fu PP, Xia Q, Zhao Y, Wang S, Yu H, Chiang H-M. Phototoxicity of herbal plants and herbal products. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013;31:213-255.
84. Inbaraj J, Kukielczak B, Bilski P, Sandvik S, Chignell C. Photochemistry and photocytotoxicity of alkaloids from goldenseal (Hydrastis canadensis L). 1. berberine. Chem Res Toxicol 2001;14:1529-1534.
85. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism 2008;57:712-717.
86. Marin-Neto JA, Maciel BC, Secches AL, Gallo Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol 1988;11:253-260.
87. Fung FY, Linn YC. Developing traditional chinese medicine in the era of evidence-based medicine: current evidences and challenges. Evid Based Complement Alternat Med 2015;425037:8.
88. Bateman J, Chapman RD, Simpson D. Possible toxicity of herbal remedies. Scott Med J 1998;43:7-15.
89. Linn YC, Lu J, Lim LC, Sun H, Sun J, Zhou Y, et al. Berberine-induced haemolysis revisited: safety of thizoma coptidis and cortex phellodendri in chronic haematological diseases. Phytother Res 2012;26:682-686.
90. Lo SN, Chang YP, Tsai KC, Chang CY, Wu TS, Ueng YF. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Toxicol Appl Pharmacol 2013;272:671-680.
91. Vrzal R, Zdařilová A, Ulrichová J, Bláha L, Giesy JP, Dvořák Z. Activation of the aryl hydrocarbon receptor by berberine in HepG2 and H4IE cells: biphasic effect on CYP1A1. Biochem Pharmaco 2005;70:925-936.
92. Chu CC, Pan KL, Yao HT, Hsu JT. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism. Biotechnol Bioeng 2011;108:2932-2940.
93. Han Y-L, Yu H-L, Li D, Meng X-L, Zhou Z-Y, Yu Q, et al. In vitro inhibition of huanglian [rhizoma coptidis (L.)] and its six active alkaloids on six cytochrome P450 isoforms in human liver microsomes. Phytother Res 2012;25:1660-1665.
94. Zhao Y, Hellum BH, Liang A, Nilsen OG. The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetryahydopalmatine, neferine and berberine. Phytother Res 2012;26:277-283.
95. Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003;31:1391-1397.
96. Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HJ. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol 2012;68:217-217.
97. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005;61:567-572.